Molecular Pathways Molecular Pathways : BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation

Cancers acquire mutations in cooperating pathways that sustain their growth and survival. To support continued proliferation, tumor cells adapt their metabolism to balance energy production with their augmented biosynthetic needs. Although most normal differentiated cells use mitochondrial oxidative phosphorylation (OXPHOS) as the bioenergetic source, cancer cells have been proposed to rely principally on cytoplasmic glycolysis. The molecular basis for this shift, termed the Warburg effect, is the subject of intense investigation, because mechanistic understanding may lead to novel approaches to target the altered metabolism of cancer cells. Recently, mutations BRAF(V600E) have emerged as a major regulator of metabolic homeostasis. Melanoma cells may use a metabolic shift to circumvent BRAF(V600E)-induced senescence though limiting their reliance on OXPHOS and promote proliferation. Furthermore, BRAF(V600E) acts to suppress expression of the melanocyte master regulator microphthalmia-associated transcription factor (MITF) and the mitochondrial biogenesis coactivator PGC1α. Accordingly, therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming in melanoma cells and elevates OXPHOS through increased MITF–PGC1α levels. BRAF-targeted drugs modulate the metabolic state of malignant melanoma cells, and counteracting these adaptive responses using pharmacologic agents may prove useful in combinatorial therapeutic strategies. Clin Cancer Res; 20(9); 2257–63. ©2014 AACR.

[1]  L. Cantley,et al.  Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. , 2013, Molecular cell.

[2]  L. Cantley,et al.  Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma , 2013, Proceedings of the National Academy of Sciences.

[3]  G. McArthur,et al.  The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma , 2013, Clinical Cancer Research.

[4]  T. Shlomi,et al.  A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence , 2013, Nature.

[5]  F. Berrino,et al.  Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects , 2013, Oncogene.

[6]  P. Puigserver,et al.  PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.

[7]  Jun S. Song,et al.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.

[8]  Jun S. Song,et al.  BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition , 2013, Proceedings of the National Academy of Sciences.

[9]  Liu Wei,et al.  LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.

[10]  Jonathan E. Shoag,et al.  PGC-1 coactivators regulate MITF and the tanning response. , 2013, Molecular cell.

[11]  J. Chesney,et al.  Molecular Pathways: Regulation of Metabolism by RB , 2012, Clinical Cancer Research.

[12]  J. Kirkwood,et al.  Importance of glycolysis and oxidative phosphorylation in advanced melanoma , 2012, Molecular Cancer.

[13]  J. Kirkwood,et al.  Mitochondrial Respiration - An Important Therapeutic Target in Melanoma , 2012, PloS one.

[14]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[15]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[16]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[17]  H. Horlings,et al.  Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. , 2012, Genes & development.

[18]  P. Bahadoran,et al.  Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells , 2012, Oncogene.

[19]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[20]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[21]  G. Giaever,et al.  Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. , 2011, Cancer cell.

[22]  S. Gygi,et al.  A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. , 2011, Cancer cell.

[23]  K. Brown,et al.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.

[24]  S. Puig,et al.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.

[25]  Jeff S. Jasper,et al.  The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. , 2011, Cancer cell.

[26]  D. Fisher,et al.  Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF , 2011, Proceedings of the National Academy of Sciences.

[27]  D. Fisher,et al.  Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[29]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[30]  V. Mootha,et al.  Nutrient‐sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis , 2011 .

[31]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[32]  C. Wellbrock,et al.  BRAF as therapeutic target in melanoma. , 2010, Biochemical pharmacology.

[33]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[34]  M. Brown,et al.  Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .

[35]  M. Berridge,et al.  Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. , 2010, Rejuvenation research.

[36]  I. Nagtegaal,et al.  BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[37]  L. Pollak Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.

[38]  G. Merlino,et al.  Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAFV600E , 2009, PloS one.

[39]  L. Chin,et al.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. , 2009, Molecular cell.

[40]  Julien Verrax,et al.  Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.

[41]  Carlo Gambacorti-Passerini,et al.  BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells , 2008, Molecular Cancer Research.

[42]  Y. Yang,et al.  Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of T47D human breast cancer cells. , 2007, Toxicology letters.

[43]  Joanne M. Morrisey,et al.  Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum , 2007, Nature.

[44]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[45]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[46]  David P. Davis,et al.  Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. , 2006, Cancer research.

[47]  R. Franklin,et al.  Altered metabolism and mitochondrial genome in prostate cancer , 2006, Journal of Clinical Pathology.

[48]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[49]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[50]  L. Zon,et al.  BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma , 2005, Current Biology.

[51]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[52]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[53]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[54]  H. Kusuhara,et al.  Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. , 2003, Molecular pharmacology.

[55]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[56]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[57]  Ronald A. DePinho,et al.  Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation , 2002, Nature.

[58]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[59]  Sridhar Ramaswamy,et al.  Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.

[60]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[61]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[62]  V. Ferrans,et al.  Ras Proteins Induce Senescence by Altering the Intracellular Levels of Reactive Oxygen Species* , 1999, The Journal of Biological Chemistry.

[63]  D. Woods,et al.  Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.

[64]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[65]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[66]  N. Jenkins,et al.  Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein , 1993, Cell.

[67]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[68]  W. Kaelin,et al.  Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. , 2011, Cold Spring Harbor symposia on quantitative biology.

[69]  R. Weichselbaum,et al.  Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  D. Hardie,et al.  AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. , 2005, Cell metabolism.

[71]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.